Vimarsana
Biggest News Aggregation in the World

Page 6 - Codexis Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Codexis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Codexis Inc Today - Breaking & Trending Today

Brokerages Set Codexis, Inc. (NASDAQ:CDXS) PT at $7.17 - Vimarsana News

Brokerages Set Codexis, Inc. (NASDAQ:CDXS) PT at $7.17

Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year […]

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting - Vimarsana News

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

01.02.2024 - TnX transposase development collaboration leverages strengths of both companiesBEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) - seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: ... Seite 1

Synthetic Biology Technology Market Report 2024: Analysis - Vimarsana News

Synthetic Biology Technology Market Report 2024: Analysis

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The

Healthcare Specialty Enzymes Market Analysis with Forecast - Vimarsana News

Healthcare Specialty Enzymes Market Analysis with Forecast

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The

Codexis, Inc. (NASDAQ:CDXS) Receives $7.17 Average PT from Analysts - Vimarsana News

Codexis, Inc. (NASDAQ:CDXS) Receives $7.17 Average PT from Analysts

Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective […]

Source: wkrb13.com